In the last years XPD Lys751Gln polymorphism has been investigated in different hematological malignancies, such as acute myeloid and lymphoblastic leukemia, but with contradictory results [35–41]. This evidence concerns the gene ERCC2 and acute lymphoblastic leukemia.